Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference

SAN DIEGO–(BUSINESS WIRE)–#biotechnews–Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a virtual fireside chat at the 36th Annual Roth Conference scheduled for March 17-19, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California.


Details regarding the Revelation fireside chat are as follows:

35th Annual Roth Conference Presentation Details

Date:

Monday, March 18, 2023

Time:

11:00 a.m. Pacific Time

Location:

The Ritz Carlton, Laguna Niguel, CA

Webcast:

REVB Webcast Link

A live webcast of the presentation will also be available in the Investor Relations section of Revelation’s website at https://www.revbiosciences.com. A replay of the presentation will be available on Revelation’s website for 30 days following the event.

Mr. Rolke will be available for one-on-one meetings throughout the conference in person and virtually.

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including GEMINI-SSI as a prevention for post-surgical infection, GEMINI-AKI as a prevention for acute kidney injury, and GEMINI-CKD for the treatment of chronic kidney disease.

For more information on Revelation, please visit www.RevBiosciences.com.

Contacts

Sandra Vedrick

Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.

Email: [email protected]

and

Chester Zygmont, III

Chief Financial Officer
Revelation Biosciences Inc.

Email: [email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.